Articles By Estel Grace Masangkay

81. Texas A&M On Standby For Ebola Drug Mass Production 10/15/2014

    The Texas A&M Health Science Center is one of the three sites on standby for mass production of Z-MAPP, an investigational drug for Ebola awaiting approval from the U.S. Food and Drug Administration (FDA).

82. Natural Molecule Can Reverse Autoimmune Disease Response 10/13/2014

    Researchers at the Brigham and Women's Hospital (BWH) reported the results of a new study investigating a natural molecule that can be used as a potential treatment to reverse autoimmune response and disease progression.

83. DNAtrix's Glioma Treatment Granted FDA Orphan Drug Status 10/13/2014

    DNAtrix, a company developing modified viruses as treatment against aggressive types of cancer, announced that its DNX-2401has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of malignant glioma.

84. FDA Clears Vivolux Cancer Drug Phase 1/2 Trial In Myeloma 10/10/2014
    Vivolux reported that it has received the green light from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 1/2 trial for VLX1570 in relapsed and/or refractory multiple myeloma.
85. EMD Serono Enters Alliance To Develop Anti-Cancer Drugs 10/10/2014

    Merck’s biopharmaceutical division EMD Serono announced that it has entered into an alliance with The Institute of Cancer Research (ICR) and the Wellcome Trust in London to jointly develop and license potential anti-cancer drugs.

86. Ariad's Lung Cancer Drug Gets FDA Breakthrough Status 10/8/2014

    Oncology company Ariad Pharmaceuticals announced that its investigational drug AP26113 has been designated Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) as treatment for crizotinib-resistant patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

87. NKT's Sickle Cell Drug Fast Tracked By The FDA 10/7/2014

    Privately held biotech firm NKT Therapeutics announced that its lead therapeutic NKTT120 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of sickle cell disease.

88. Neurocrine Kick-Starts Trial For Tourette Syndrome Drug 10/7/2014

    Clinical stage drug discovery company Neurocrine Biosciences reported that it has initiated the clinical trial of its VMAT2 inhibitor NBI-98854 in adult and pediatric patients with Tourette syndrome.

89. GSK, NewLink Race To Bring Ebola Vaccines Online By 2015 10/6/2014

    The World Health Organization revealed that pharmaceutical companies GlaxoSmithKline and NewLink Genetics are working double time to ramp up their capacity to produce Ebola vaccine candidates. The companies hope to bring an effective Ebola vaccine online by 2015, reports Reuters.

90. NIH Inks 7 Vaccine Adjuvant Discovery Contracts 10/2/2014

    The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has signed a total of seven new vaccine adjuvant discovery contracts with different institutions, including five leading universities.